Phaseline

Companies › HRYZ Biotech

HRYZ Biotech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MASCT-I
Dendritic cell and effector T cell therapy
–Phase 2LeiomyosarcomaFeb 2027
HRYZ-T101 Injection
HPV18-specific TCR-engineered T cells
–Phase 1Cervical CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06277154MASCT-IPhase 2LeiomyosarcomaOncologyFeb 2027
NCT05952947HRYZ-T101 InjectionPhase 1Cervical CancerOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Diakonos Oncology iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.